A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma

2021 ◽  
Author(s):  
Daisuke Tsutsumi ◽  
Tatsuya Hayama ◽  
Katsuhiro Miura ◽  
Akihiro Uchiike ◽  
Shinya Tsuboi ◽  
...  
Keyword(s):  
B Cell ◽  
Adverse Reactions ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Administration Protocol

scholarly journals Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

2021 ◽  
Author(s):  
Liangliang Ren ◽  
Ling Li ◽  
Lei Zhang ◽  
Xin Li ◽  
Xiaorui Fu ◽  
...  
Keyword(s):  
B Cell ◽  
Survival Time ◽  
Clinical Studies ◽  
Adverse Reactions ◽  
Cell Lymphoma ◽  
Combined Treatment ◽  
Objective Response ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

AbstractLimited treatment options are available for relapsed or refractory diffuse large B cell lymphoma (RR DLBCL). Few clinical studies have reported the use of Ibrutinib, a covalent Bruton Tyrosine kinase (BTK) inhibitor, in RR DLBCL. There are relatively few clinical studies about Ibrutinib in RR DLBCL now. We retrospectively investigated the safety and efficacy of Ibrutinib (alone or in combination with other drugs) in patients with RR DLBCL. We reviewed the medical records of 40 RR DLBCL patients who received Ibrutinib alone or in combination with other drugs in our hospital from June 2018 to August 2020. The objective response rate (ORR) of RR DLBCL patients on Ibrutinib was 22.5%. The median progression free survival time (PFS) was 13.0 months (95% CI 8.914–17.086), and the median overall survival time (OS) was 15.0 months (95% CI 11.931–18.089). Rash (25.0%) and fatigue (25.0%) were the most common adverse reactions in this study. The application of Ibrutinib to patients with RR DLBCL has good short-term efficacy, and the adverse reactions are well tolerated. Combined treatment of Ibrutinib with other drugs has been found to more effective than Ibrutinib therapy alone.

Abstract #812: Primary B Cell Lymphoma of Pituitary Presenting with Hypopituitarism and Dual Natremic Abnormalities

2015 ◽  
Vol 21 ◽  
pp. 153-154
Author(s):  
Abhijana Karunakaran ◽  
Kadapalakere Reddy ◽  
Anshu Alok ◽  
Manav Batra ◽  
Ajay Chaudhuri ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma

Lymphome

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Maligne Lymphome ◽  
Interim Pet ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Sign in / Sign up

Export Citation Format

Share Document